Showing results (171-180 of 183) with videos related to
Sort By:
Pageof 19
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.Neuro-Oncology|April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOGDeborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.Cancer Research Communications|July 10, 2023
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine GlioblastomaMichal Nisnboym, Sarah R Vincze, Zujian Xiong, et al.Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.Nature Communications|August 10, 2024
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccinePauline Latzer, Henning Zelba, Florian Battke, et al.Cancer Discovery|October 12, 2023
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD ConsortiumAnirban Das, Nicholas R Fernandez, Adrian Levine, et al.Pageof 19